A telephonic Detroit Pistons audio replay of the webcast will be available

A telephonic studies detroit pistons audio replay pistons tells of the webcast will be available beginning at 4:45p.m PT on January 15, 2009 through 4:45 p.m PT on January 22, 2009. Accessnumbers for this replay are: 1-800-642-1687 (U.S./Canada) and 1-706-645-9291(international); conference ID number is 75928763. About GenentechFounded more than 30 years ago, Genentech is a leading biotechnology companythat discovers, develops, manufactures and commercializes medicines to treatpatients with significant unmet medical needs. The company has headquarters inSouth San Francisco, California and is listed on the New York Stock Exchangeunder the symbol DNA. For additional information about the company, please visit About Genentech’s Commitment to Patient AccessGenentech is committed to patients having access to our therapies. Through itsGenentech Access Solutions program, the company provides patients and healthcareproviders with coverage and reimbursement support, patient assistance andinformational resources. Patient assistance support is for those eligiblepatients in the United States who do not have insurance coverage or who cannotafford their out-of-pocket co-pay costs.

Since 1985, when its first product wasapproved, Genentech has donated approximately $1.3 billion in free medicine touninsured patients through the Genentech Access to Care Foundation (GATCF) andother product donation programs detroit news pistons nba.com – pistons . Since 2005, Genentech has also donatedapproximately $250 million to various independent, non-profit organizations thatprovide financial assistance to eligible patients who cannot access neededmedical treatment due to co-pay costs chauncey billups . For information on Genentech`s latest business and product development eventsplease refer to This press release contains forward-looking statements regarding submitting morethan ten regulatory applications, the potential to receive four FDA approvals,and expected growth in non-GAAP earnings per share for 2009 rasheed wallace . Such statements arepredictions and involve risks and uncertainties such that actual results maydiffer materially ben wallace . Such risks and uncertainties include, but are not limited to,the need for additional data, data analysis or clinical studies; the results ofclinical trials; BLA preparation and decision making; FDA actions or delays;failure to obtain or maintain FDA approval; difficulty in obtaining materialsfrom suppliers; unexpected safety, efficacy, manufacturing or distributionissues for Genentech or its contract/collaborator manufacturers; productwithdrawals; competition; efficacy data concerning any Genentech product whichshows or is perceived to show similar or improved treatment benefit at a lowerdose or shorter duration of therapy; pricing decisions by Genentech or itscompetitors; Genentech’s ability to protect its proprietary rights; the outcomeof, and expenses associated with, litigation or legal settlements; cost ofsales, other expenses and indebtedness; variations in collaborator sales andexpenses; fluctuations in contract revenue and royalties; actions by Roche thatare adverse to the interests of Genentech; the outcome of, or developmentsconcerning, Roche’s proposal to acquire Genentech’s outstanding shares;decreases in third party reimbursement rates; the ability of wholesalers toeffectively distribute Genentech`s products; and changes in accounting or taxlaws or the application or interpretation of such laws. Please also refer to therisk factors identified in Genentech’s periodic reports filed with theSecurities and Exchange Commission. Genentech disclaims, and does not undertake,any obligation to update or revise forward-looking statements in this pressrelease.

1 Genentech’s non-GAAP operating revenue and royalty revenue exclude recognitionof deferred royalty revenue associated with the acquisition of Tanox, Inc allen iverson detroit piston . of $4million for both the fourth quarters of 2008 and 2007, $15 million for the fullyear 2008, and $6 million for the full year 2007 tayshaun prince . Genentech’s non-GAAP netincome and non-GAAP earnings per share exclude the after-tax impact of certainitems associated with the acquisition of Tanox (including recurring recognitionof deferred royalty revenue, recurring amortization of intangible assets,in-process research and development expenses [Q3 2007 only], a gain pursuant toEmerging Issues Task Force Issue No pistons basketball . 04-1 [Q3 2007 only], and asset impairmentcharges [Q3 2008 only]); recurring charges related to the 1999 redemption ofGenentech’s stock by Roche Holdings, Inc.; litigation-related and similarspecial items (in 2008, amount includes the net settlement related to the Cityof Hope (COH) trial judgment and additional costs accrued based on the status ofnegotiations between the parties on amounts owed for periods subsequent to theoriginal court judgment rendered in 2002); employee stock-based compensationexpense; and certain expenses incurred by the company on behalf of the SpecialCommittee in connection with its review of the Roche Proposal, as well as legalcosts incurred in defense of the Special Committee and/or its individual membersin shareholder lawsuits filed in connection with the Roche Proposal pistons hat . Thedifferences in non-GAAP and GAAP amounts are reconciled in the accompanyingtables and on 2 Full-year 2008 results include a net favorable adjustment of $0.16 per sharerelated to the COH contract dispute and litigation settlement, offset byintangibles amortization related to the 1999 redemption of Genentech’s stock byRoche and the 2007 acquisition of Tanox, Roche Proposal-related fees incurred onbehalf of the Special Committee, and other items related to the acquisition ofTanox, including recognition of deferred royalty revenue and asset impairmentcharges, totaling $0.12 per share. Full-year 2007 results include accruedinterest and bond costs related to the COH trial judgment, intangiblesamortization related to the 1999 redemption of Genentech’s stock by Roche andthe 2007 acquisition of Tanox, partially offset by recognition of deferredroyalty revenue related to the acquisition of Tanox Pistons Palace Of Auburn Hills tickets . 3 Genentech’s full-year 2008 non-GAAP reported COS, R&D and MG&A expensesexclude the effects of employee stock-based compensation expense of $82 million,$152 million, and $165 million, respectively, and MG&A expense also excludesasset impairment charges of $15 million related to the acquisition of Tanox andcharges of $14 million associated with supporting the Special Committee inconnection with the Roche Proposal.

Full-year 2007 non-GAAP reported COS, R&Dand MG&A expenses exclude the effects of employee stock-based compensationexpense of $71 million, $153 million, and $179 million, respectively.Genentech’s fourth quarter 2008 non-GAAP reported COS, R&D and MG&A expensesexclude the effects of employee stock-based compensation expense of $20 million,$33 million, and $35 million, respectively, and MG&A expense also excludescharges of $8 million associated with supporting the Special Committee inconnection with the Roche Proposal detroit pistons baby . Fourth quarter 2007 non-GAAP reported COS,R&D and MG&A expenses exclude the effects of employee stock-based compensationexpense of $22 million, $39 million, and $42 million, respectively pistons schedule . Thedifferences in non-GAAP and GAAP amounts are reconciled in the accompanyingtables and on GENENTECH, INC pistons watch . CONSOLIDATED STATEMENTS OF INCOME (In millions, except per share amounts) (Unaudited)Three MonthsYearEnded December 31,Ended December 31,2008 2007 20082007 Revenues: Product sales $2,981 $2,349 $10,531 $9,443Royalties6075582,539 1,984Contract revenue 11963 348 297Total operating revenues 3,7072,97013,41811,724Costs and expenses: Cost of sales5033441,744 1,571Research and development 7576182,800 2,446Marketing, general and administrative7186922,405 2,256Collaboration profit sharing 3222751,228 1,080Write-off of in-process research and development related to acquisition(1) — 77 Gain on acquisition(1) — (121)Recurring amortization charges related to redemption and acquisition(2)43 43 172 132Special items: litigation-related-14 (260) 54 Total costs and expenses 2,3431,9868,089 7,495 Operating income 1,3649845,329 4,229 Other income (expense): Interest and other income, net(3)51 40 184 273Interest expense (25) (22) (82 ) (76 )Total other income, net26 18 102 197 Income before taxes1,3901,0025,431 4,426 Income tax provision 4593702,004 1,657 Net income$931 $632 $3,427$2,769 Earnings per share: Basic $0.88$0.60$3.25 $2 Pistons Palace Of Auburn Hills tickets – wikipedia .63 Diluted $0.87$0 Pistons Palace Of Auburn Hills .59$3.21 $2.59Weighted average shares used to compute earnings per share:Basic1,0521,0531,053 1,053Diluted1,0651,0681,067 1,069 (1)Represents non-recurring items related to our 2007 acquisition of Tanox, Inc pistons jerseys . (2)Represents the amortization of intangible assets related to the 1999 redemption of our common stock by Roche Holdings, Inc and our 2007 acquisition of Tanox, Inc. (3)”Interest and other income, net” includes interest income, realized gains and losses from the sale of debt and equity securities, write-downs for other -than-temporary impairments in the fair value of certain debt and equity securities and mark-to-market valuation adjustments for various securities Pistons Palace Of Auburn Hills tickets .

For further detail, refer to our web site at, INC.RECONCILIATION OF GAAP TO NON-GAAP NET INCOME(In millions, except per share amounts)(Unaudited) Three MonthsYear Ended December 31,Ended December 31, 2008 2007 2008 2007GAAP net income$931 $632 $3,427 $2,769Royalty revenue(1)(4 ) (4 ) (15) (6 ) Employee stock-based compensation expense under FAS 123R included in the followingoperating expenses:Cost of sales 20 22 82 71Research and development33 39 152153 Marketing, general and administrative 35 42 165179Asset impairment charges(2) –15 -Roche Proposal-related fees incurred on 8-14 -behalf of the Special Committee(3)Write-off of in-process research and—77 development related to acquisition(4) Gain on acquisition(4)—(121 ) Recurring amortization charges related to 43 43 172132redemption and acquisition(5) Special items: litigation-related(6)-14 (260 ) 54 Income tax effect(7)(52) (51) (109 ) (166 ) Non-GAAP net income$1,014 $737 $3,643 $3,142 Non-GAAP earnings per share: Diluted$0.95$0.69$3.42$2.94Non-GAAP weighted average shares used tocompute earnings per share(8): Diluted 1,0631,0661,0651,068(1)Represents recognition of deferred royalty revenue related to our 2007 acquisition of Tanox, Inc.(2)Represents asset impairment charges related to our 2007 acquisition of Tanox, Inc . recorded as marketing, general and administrative expense in the third quarter of 2008 pistons playoff tickets . (3)Represents costs incurred by the company on behalf of the Special Committee in connection with its review of the Roche Proposal, as well as legal costs incurred in defense of the Special Committee and/or its individual members in shareholder lawsuits filed in connection with the Roche Proposal detroitpistons . (4)Represents non-recurring items related to our 2007 acquisition of Tanox, Inc.(5)Represents the amortization of intangible assets related to the 1999 redemption of our common stock by RocheHoldings, Inc and our 2007 acquisition of Tanox, Inc Pistons Palace Of Auburn Hills – nba . (6)Includes accrued interest and bond costs in the fourth quarter and full year of 2007, and the net settlement in the full year of 2008 related to the City of Hope trial judgment. Amount for the full year of 2008 also includes additional costs accrued related to the City of Hope contract dispute based on the status of negotiations between the parties on amounts owed for periods subsequent to the original court judgment rendered in 2002.(7)Reflects the income tax effects of excluding employee stock-based compensation expense under FAS 123R, recurring charges related to the redemption of our common stock, litigation-related special items, items related to our acquisition of Tanox, Inc. and items related to the Roche Proposal.(8)Weighted average shares used to compute non-GAAP diluted earnings per share were computed exclusive of themethodology used to determine dilutive securities under FAS 123R.

For the latest news, real-time flight information, parkingavailability or further details regarding the many services provided at DFWInternational Airport, log on to AMR Corp. We will explore many possible scenarios, and may even work out a few possible trades. Michael Bender Shares Information Needed to Prevent Illegal Street Racing,Protect LivesSAN DIEGO, March 25 /PRNewswire/ — “New Model. In today`s strained economy, hundreds of leading financial institutions areturning to Digital Insight online solutions to better meet the financialmanagement needs of consumers and businesses Pistons Palace Of Auburn Hills tickets – nba .

Kenny Anderson – Averaged 23 points, 7.0 assists per game.12 Brad Daugherty – Two-time first team All ACC No 3. The Kings are 6-18 straight up overall, and while they normally have one of the bigger home court advantages in the league, this has not been the case this year as they are just 4-9 at Arco Arena. and GDX Network, Inc., visit the GDXWeb site at http:// IIJFounded in 1992, Internet Initiative Japan Inc. After Chicago, the commission travels to Tokyo from April16-19, Rio de Janeiro from April 29-May 2 and Madrid from May5-8. It’s just unfortunate that one of the league’s premier defensive playmakers is suspended up in an alcohol treatment facility when half of the players on your field Sunday will likely still be drunk pistons.com .Goodell should reinstate Pac-Man quick because the game needs him, and he needs the game.. (the “Company”) announced today thecommencement of a cash tender offer for any and all of the approximately$99.8 million aggregate principal amount outstanding of 7.017% Notes due2016 (the “Notes”) issued by MaruEnergy Trinidad, LLC (f/k/a MirantTrinidad Investments, LLC) (“MET”).